Renal hemodynamics in heart failure: Implications for treatment

Current Opinion in Nephrology and Hypertension

Volumn 17, Issue 1, 2008, Pages 87-92

  Rea, Mark E ^a   Dunlap, Mark E ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Cardiorenal syndrome; Heart failure; Renin angiotensin system; Sympathetic nervous system

Indexed keywords

ADENOSINE A1 RECEPTOR ANTAGONIST; ALDOSTERONE ANTAGONIST; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGIPRESSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN; GLYCERYL TRINITRATE; LOOP DIURETIC AGENT; NATRIURETIC FACTOR; NESIRITIDE; NEUROHORMONE; OMAPATRILAT; PLACEBO; SODIUM; THIAZIDE DIURETIC AGENT; TOLVAPTAN; VASOPRESSIN; WATER;

ADRENERGIC SYSTEM; ARTERIAL STIFFNESS; AUTOREGULATION; BLOOD VESSEL INJURY; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR SYSTEM; CHEMICAL ANALYSIS; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPREHENSION; CONTINUOUS INFUSION; FLUID RETENTION; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HOMEOSTASIS; HUMAN; HYPERTENSION; KIDNEY; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; MONOTHERAPY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM RETENTION; SYMPTOM; VASOCONSTRICTION; WATER RETENTION;

ANIMALS; HEART FAILURE; HEMODYNAMICS; HOMEOSTASIS; HUMANS; KIDNEY;

EID: 37349050644     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3282f357da     Document Type: Review

References (32)

1. Wencker D. Acute cardio-renal syndrome: progression from congestive heart failure to congestive kidney failure. Curr Heart Fail Rep 2007; 4:134-138. This is an excellent review of the pathophysiology of cardiorenal syndrome and describes the progression from congestive heart failure to congestive kidney failure.
2. O'Rourke MF, Hashimoto J. Mechanical factors in arterial aging: a clinical perspective. J Am Coll Cardiol 2007; 50:1-13. This paper describes the mechanical changes associated with aging of the arteries and the hemodynamic effect these changes have on the microcirculation.
3. Greenberg SM. Small vessels, big problems. N Engl J Med 2006; 354:1451-1453.
4. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005; 46:1785-1791.
5. Lee CYW, Burnett JC. Natriuretic peptides and therapeutic applications. Heart Fail Rev 2007; 12:131-142. This is an excellent, comprehensive review of the natriuretic peptides, including their pharmacologic properties and clinical utility in the treatment of heart failure.
6. Stevens TL, Burnett JC, Kinoshita M, et al. A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. J Clin Invest 1995; 95:1101-1108.
7. Boerrigter G, Burnett JC. Pathophysiology of the cardiorenal syndrome in acute heart failure. In: O'Connor CM, Stough WG, Gheorghiade M, Adams KF, editors. Managing acute decompensated heart failure. London: Taylor and Francis; 2005. pp. 113-123.
8. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004; 43:61-67.
9. Fonarow GC, Adams KF, Abraham WT, et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005; 293:572-580.
10. Brater DC. Diuretic therapy. N Engl J Med 1998; 339:387-395.
11. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
12. Thomson S, Bao D, Deng A, Vallon V. Adenosine formed by 50-nucleotidase mediates tubuloglomerular feedback. J Clin Invest 2000; 106:289-298.
13. Lucas DG, Hendrick JW, Sample JA, et al. Cardiorenal effects of adenosine subtype 1 (A1) receptor inhibition in an experimental model of heart failure. J Am Coll Surg 2002; 194:603-609.
14. Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002; 105:1348-1353.
15. Agostoni PG, Marenzi GC, Lauri G, et al. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. Am J Med 1994; 96:191-199.
16. Guazzi MD, Agostoni P, Perego B, et al. Apparent paradox of neurohormonal axis inhibition after body fluid volume depletion in patients with chronic congestive heart failure and water retention. Br Heart J 1994; 72:534-539.
17. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007; 49:675-683. This paper describes the findings of the UNLOAD trial in which ultrafiltration produced greater weight and fluid loss than intravenous diuretics in the treatment of heart failure.
18. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE inhibitor trials. JAMA 1995; 273:1450-1456.
19. Bakris G, Weir M. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2003; 160:685-693.
20. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362:759-766.
21. Epstein M. Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis 2001; 37:677-688.
22. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709-717.
23. Cleland AG, Abdellah AT, Khaleva O, et al. Clinical trials update from the European Society of Cardiology Congress 2007: 3CPO, ALOFT, PROSPECT and statins for heart failure. Eur J Heart Fail 2007; 9:1070-1073.
24. Gheorghiade M, Gattis WA, O'Connor CM, et al. Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial (ACTIV). JAMA 2004; 291:1963-1971.
25. Gheorghiade M, Konstam MA, Burnett JC, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA 2007; 297:1332-1343. This report of the EVEREST trial showed there were short-term improvements in heart failure symptoms in patients treated with tolvaptan as compared with placebo.
26. Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 2007; 297:1319-1331. This report of the EVEREST trial showed there were no long-term improvements in mortality or heart-failure morbidity in patients treated with tolvaptan as compared with placebo.
27. Colluci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000; 343:246-253.
28. Publication Committee for the VMAC Investigators (Vasodilation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002; 287:1531-1540.
29. Mitrovic V, Luss H, Nitsche K, et al. Effects of the renal natriuretic peptide urodilantin (ularitide) in patients with decompensated chronic heart failure: A double-blind placebo-controlled, ascending-dose trial. Am Heart J 2005; 150:1239e1-1239e8.
30. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106:920-926.
31. Boerrigter G, Burnett JC. Endothelin in neurohormonal activation in heart failure. Coron Artery Dis 2003; 14:495-500.
32. Torre-Amione G, Young JB, Colucci WS, et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2003; 42:140-147.